Monoclonal Antibody to Semaphorin 4D (SEMA4D) Homo sapiens (Human) Monoclonal antibody

CD100; A8; BB18; GR3; M-Sema G; M-Sema-G; SEMAJ; Coll-4; Sema Domain,Immunoglobulin Domain(Ig),Transmembrane Domain(TM)and Short Cytoplasmic Domain 4D

Add to Cart Distributors
Overview
Properties
  • SourceMonoclonal antibody preparation, Host Mouse
  • Ig Isotype IgG, Clone Number n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelNone
  • Immunogen n/a
  • Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
  • TraitsLiquid, Concentration 1mg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Monoclonal Antibody to Semaphorin 4D (SEMA4D) Packages (Simulation)
  • Monoclonal Antibody to Semaphorin 4D (SEMA4D) Packages (Simulation)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a mouse monoclonal antibody raised against SEMA4D. It has been selected for its ability to recognize SEMA4D in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatmentPubmed:25395071
  • Genome-wide analysis identifies an african-specific variant in SEMA4D associated with body mass index.pubmed:28296344
  • A Revised Staging System for Waldenström's Macroglobulinemia10.1016/j.clml.2017.07.146
  • Extramedullary Multiple Myeloma: Clinical Features and Prognosis in Argentina10.1016/j.clml.2017.07.144
  • Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myelomaPubmed:29748532
  • A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphorin 4D in plasmaPubmed: 30879960
  • Pathological and therapeutic implications of eosinophil-derived semaphorin 4D in eosinophilic chronic rhinosinusitisPubmed: 32035658

Recommend products